Temsirolimus (CCI-779): Early results of an mTOR inhibitor in renal carcinoma

被引：0
|
作者：
Hudes, GR [1 ]
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：18 / 18
页数：1
相关论文
共 50 条
  • [11] Lipase-catalyzed regioselective esterification of rapamycin: Synthesis of temsirolimus (CCI-779)
    Gu, JX
    Ruppen, ME
    Cai, P
    [J]. ORGANIC LETTERS, 2005, 7 (18) : 3945 - 3948
  • [12] A phase II study of temsirolimus (CCI-779) in patients with advanced leukemias.
    Yee, KWL
    Garcia-Manero, G
    Thomas, D
    Ani, FRK
    Verstovsek, S
    Andreeff, M
    Dancey, JE
    Giles, FJ
    [J]. BLOOD, 2004, 104 (11) : 214B - 214B
  • [13] mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer
    Yu, K
    Toral-Barza, L
    Discafani, C
    Zhang, WG
    Skotnicki, J
    Frost, P
    Gibbons, JJ
    [J]. ENDOCRINE-RELATED CANCER, 2001, 8 (03) : 249 - 258
  • [14] A phase IINCCTG "window of opportunity front-line" study of the mTOR inhibitor, CCI-779 (temsirolimus) given as a single agent in patients with advanced NSCLC
    Molina, Julian R.
    Mandrekar, Sumithra J.
    Rowland, Kendrith
    Reuter, Nicholas F.
    Jett, James R.
    Marks, Randolph
    Schild, Stevens E.
    Adjei, Alex A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S413 - S413
  • [15] mTOR inhibitor CCI-779 enhances the efficacy of radiotherapy in a cisplatin-resistant HNSCC cell line
    Ekshyyan, Oleksandr
    Rong, Xiaohua
    Caldito, Gloria
    Keating, Patrick
    Ifeanyi, Chuka
    Clavenna, Matthew
    Chang, John
    Ampil, Federico
    Nathan, Cherie-Ann
    [J]. CANCER RESEARCH, 2009, 69
  • [16] In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer
    Ito, D
    Fujimoto, K
    Mori, T
    Kami, K
    Koizumi, M
    Toyoda, E
    Kawaguchi, Y
    Doi, R
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (09) : 2337 - 2343
  • [17] The mTOR inhibitor, CCI-779, restores tamoxifen response in breast cancer cells with high Akt activity
    deGraffenried, L
    Friedrichs, W
    Fulcher, L
    Silva, J
    Roth, R
    Hidalgo, M
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 : S158 - S158
  • [18] Molecular mechanisms of the mTOR inhibitor temsirolimus (CCI-779) antiproliferative effects in mantle cell lymphoma: Induction of cell cycle arrest, autophagy, and synergy with vorinostat (SAHA).
    Yazbeek, Victor Y.
    Georgakis, Georgios V.
    Li, Yang
    Iwado, Eiji
    Kondo, Seiji
    Younes, Anas
    [J]. BLOOD, 2006, 108 (11) : 706A - 706A
  • [19] Low expression of surrogates for mTOR pathway activation predicts resistance to CCI-779 in patients with advanced renal cell carcinoma (RCC).
    Cho, DC
    Signoretti, S
    Regan, M
    McDermott, D
    Polivy, A
    Youmans, A
    Stanbridge, E
    Atkins, M
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9133S - 9134S
  • [20] Final results of a phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
    Witzig, T
    Geyer, S
    Ghobrial, I
    Inwards, D
    Fonseca, R
    Kurtin, P
    Ansell, S
    Kaufmann, S
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 65 - 65
12345